A multimeric L2 vaccine for prevention of animal papillomavirus infections

Subhashini Jagu, Nicole Malandro, Kihyuck Kwak, Hang Yuan, Richard Schlegel, Kenneth E. Palmer, Warner K. Huh, M. Saveria Campo, Richard S Roden

Research output: Contribution to journalArticle

Abstract

It is unclear what level of neutralizing antibody is sufficient to protect cattle from experimental bovine papillomavirus type 4 (BPV4) challenge. Markedly lower, and often undetected, serum neutralizing antibody titers were associated with protection in cattle vaccinated with BPV4 L2 as compared to L1 VLP. We hypothesized that vaccination with concatemers of the N-terminal protective epitopes of L2 derived from multiple animal papillomavirus types would enhance the breadth and strength of immunity. Therefore we generated a multimeric L2 antigen derived from three bovine and three canine papillomavirus types with divergent phenotypes and purified it from bacteria. Mice vaccinated three times with this six type L2 vaccine formulated in alum or RIBI adjuvant generated robust serum neutralizing antibody titers against BPV1, BPV4 and canine oral papillomavirus (COPV). Furthermore, vaccination with this six type L2 vaccine formulated in adjuvant, like BPV1 L1 VLP, protected the mice from experimental challenge with BPV1 pseudovirus.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalVirology
Volume420
Issue number1
DOIs
StatePublished - Nov 10 2011

Fingerprint

Bovine papillomavirus 4
Papillomavirus Infections
Neutralizing Antibodies
Vaccines
Lambdapapillomavirus
Vaccination
Serum
Canidae
Epitopes
Immunity
Bacteria
Phenotype
Antigens

Keywords

  • L2
  • Papillomavirus
  • Sarcoid
  • Vaccination
  • Warts

ASJC Scopus subject areas

  • Virology

Cite this

Jagu, S., Malandro, N., Kwak, K., Yuan, H., Schlegel, R., Palmer, K. E., ... Roden, R. S. (2011). A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology, 420(1), 43-50. https://doi.org/10.1016/j.virol.2011.07.020

A multimeric L2 vaccine for prevention of animal papillomavirus infections. / Jagu, Subhashini; Malandro, Nicole; Kwak, Kihyuck; Yuan, Hang; Schlegel, Richard; Palmer, Kenneth E.; Huh, Warner K.; Campo, M. Saveria; Roden, Richard S.

In: Virology, Vol. 420, No. 1, 10.11.2011, p. 43-50.

Research output: Contribution to journalArticle

Jagu, S, Malandro, N, Kwak, K, Yuan, H, Schlegel, R, Palmer, KE, Huh, WK, Campo, MS & Roden, RS 2011, 'A multimeric L2 vaccine for prevention of animal papillomavirus infections', Virology, vol. 420, no. 1, pp. 43-50. https://doi.org/10.1016/j.virol.2011.07.020
Jagu S, Malandro N, Kwak K, Yuan H, Schlegel R, Palmer KE et al. A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology. 2011 Nov 10;420(1):43-50. https://doi.org/10.1016/j.virol.2011.07.020
Jagu, Subhashini ; Malandro, Nicole ; Kwak, Kihyuck ; Yuan, Hang ; Schlegel, Richard ; Palmer, Kenneth E. ; Huh, Warner K. ; Campo, M. Saveria ; Roden, Richard S. / A multimeric L2 vaccine for prevention of animal papillomavirus infections. In: Virology. 2011 ; Vol. 420, No. 1. pp. 43-50.
@article{2a4cdcf75066478a9be50d8ee05a2b02,
title = "A multimeric L2 vaccine for prevention of animal papillomavirus infections",
abstract = "It is unclear what level of neutralizing antibody is sufficient to protect cattle from experimental bovine papillomavirus type 4 (BPV4) challenge. Markedly lower, and often undetected, serum neutralizing antibody titers were associated with protection in cattle vaccinated with BPV4 L2 as compared to L1 VLP. We hypothesized that vaccination with concatemers of the N-terminal protective epitopes of L2 derived from multiple animal papillomavirus types would enhance the breadth and strength of immunity. Therefore we generated a multimeric L2 antigen derived from three bovine and three canine papillomavirus types with divergent phenotypes and purified it from bacteria. Mice vaccinated three times with this six type L2 vaccine formulated in alum or RIBI adjuvant generated robust serum neutralizing antibody titers against BPV1, BPV4 and canine oral papillomavirus (COPV). Furthermore, vaccination with this six type L2 vaccine formulated in adjuvant, like BPV1 L1 VLP, protected the mice from experimental challenge with BPV1 pseudovirus.",
keywords = "L2, Papillomavirus, Sarcoid, Vaccination, Warts",
author = "Subhashini Jagu and Nicole Malandro and Kihyuck Kwak and Hang Yuan and Richard Schlegel and Palmer, {Kenneth E.} and Huh, {Warner K.} and Campo, {M. Saveria} and Roden, {Richard S}",
year = "2011",
month = "11",
day = "10",
doi = "10.1016/j.virol.2011.07.020",
language = "English (US)",
volume = "420",
pages = "43--50",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A multimeric L2 vaccine for prevention of animal papillomavirus infections

AU - Jagu, Subhashini

AU - Malandro, Nicole

AU - Kwak, Kihyuck

AU - Yuan, Hang

AU - Schlegel, Richard

AU - Palmer, Kenneth E.

AU - Huh, Warner K.

AU - Campo, M. Saveria

AU - Roden, Richard S

PY - 2011/11/10

Y1 - 2011/11/10

N2 - It is unclear what level of neutralizing antibody is sufficient to protect cattle from experimental bovine papillomavirus type 4 (BPV4) challenge. Markedly lower, and often undetected, serum neutralizing antibody titers were associated with protection in cattle vaccinated with BPV4 L2 as compared to L1 VLP. We hypothesized that vaccination with concatemers of the N-terminal protective epitopes of L2 derived from multiple animal papillomavirus types would enhance the breadth and strength of immunity. Therefore we generated a multimeric L2 antigen derived from three bovine and three canine papillomavirus types with divergent phenotypes and purified it from bacteria. Mice vaccinated three times with this six type L2 vaccine formulated in alum or RIBI adjuvant generated robust serum neutralizing antibody titers against BPV1, BPV4 and canine oral papillomavirus (COPV). Furthermore, vaccination with this six type L2 vaccine formulated in adjuvant, like BPV1 L1 VLP, protected the mice from experimental challenge with BPV1 pseudovirus.

AB - It is unclear what level of neutralizing antibody is sufficient to protect cattle from experimental bovine papillomavirus type 4 (BPV4) challenge. Markedly lower, and often undetected, serum neutralizing antibody titers were associated with protection in cattle vaccinated with BPV4 L2 as compared to L1 VLP. We hypothesized that vaccination with concatemers of the N-terminal protective epitopes of L2 derived from multiple animal papillomavirus types would enhance the breadth and strength of immunity. Therefore we generated a multimeric L2 antigen derived from three bovine and three canine papillomavirus types with divergent phenotypes and purified it from bacteria. Mice vaccinated three times with this six type L2 vaccine formulated in alum or RIBI adjuvant generated robust serum neutralizing antibody titers against BPV1, BPV4 and canine oral papillomavirus (COPV). Furthermore, vaccination with this six type L2 vaccine formulated in adjuvant, like BPV1 L1 VLP, protected the mice from experimental challenge with BPV1 pseudovirus.

KW - L2

KW - Papillomavirus

KW - Sarcoid

KW - Vaccination

KW - Warts

UR - http://www.scopus.com/inward/record.url?scp=80053386924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053386924&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2011.07.020

DO - 10.1016/j.virol.2011.07.020

M3 - Article

VL - 420

SP - 43

EP - 50

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -